Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims


     Quick Explanation



    Author scientific-strength check (Xueying Yuan)
    Based on the provided publication list and citation metrics, this author’s documented work appears non-biological (finance/ESG/greenwashing) rather than biological/medical; therefore, bio-scientific “rigor/novelty” can’t be credibly assessed from biological evidence.
    Key red flag: The supplied papers are in management/finance topics (e.g., “greenwashing recognition”), not mechanistic biology.



     Long Explanation



    Author Review: Xueying Yuan
    Science-focused, skeptical, evidence-based critique of scientific strength from the information provided.
    What I can (and can’t) evaluate
    • Can evaluate: author-level citation metrics and the topical domain implied by the provided paper titles.
    • Cannot evaluate (bio-scientific): mechanistic biological rigor (experiments, controls, reproducibility, target validation, etc.) because the provided works are not biological/biomedical in title/content cues.
    • Decision consequence: Any “biology-quality” scoring would be speculative, so the bio-scientific score is necessarily limited by missing domain-relevant evidence.
    Citation metrics (from provided data)
    Works shown (domain signal from titles)
    Provided paper titles appear to be in finance/ESG/greenwashing
    • “Measuring the Unseen: A Textual Entropy Approach to Decoding New Quality Productive Forces in China’s Digital-Green Transition”
    • “Green Financial Policy, Resource Allocation and Corporate Environmental Responsibility”
    • “Multilayer asset association network, green technical cooperation innovation, and default risk: Evidence from China’s high energy-consuming industries”
    • “Exaggerating, Distracting, or Window-Dressing? An Empirical Study on Firm Greenwashing Recognition”
    Critical implication: This author’s documented research (from the provided list) looks like computational social science / finance rather than biology. Without biological methods/assays/results, bio-scientific evaluation is structurally underdetermined.
    Scientific strength assessment (constrained)
    1) Evidence base quality (for biology)
    Unassessable: No biological experiments, mechanistic models, wet-lab validation, or immunology/biochemistry endpoints were provided for these listed works.
    2) Evidence base quality (for general scholarly work)
    Citation metrics (provided: 35 total citations, h-index 3, 4 papers) suggest a modest scholarly footprint, but citation counts alone can reflect field size, indexing practices, and whether the work is in a rapidly expanding or smaller community.
    3) Reproducibility / bias risks (skeptical lens)
    Even for non-biological empirical work, reproducibility hinges on access to data, robustness checks, model transparency, and avoidance of selective reporting; however, none of that methodological detail for this specific author is included in the provided prompt.
    4) Epistemic caution about author identity
    The prompt includes OpenAlex matches that include multiple “Xueying Yuan” entries and also a different “Yong Yuan” with much larger metrics. Without unambiguous ORCID/journal-author disambiguation, there is a name-collision risk that can inflate/deflate metrics. (The review here relies only on the author metrics you explicitly provided.)
    Confidence and what would change the conclusion
    • Confidence is limited because the domain is likely non-biological and no methods/results are provided.
    • Would change if: you provide abstracts/full texts showing biological content (cell/mouse assays, molecular targets, omics assays, mechanistic pathway experiments) or you provide correct DOIs/PMIDs tied to biological work.
    • Would also change if: the cited works are misattributed due to author-name collisions; an ORCID-confirmed publication list would reduce that uncertainty.


    Feedback:    

    Updated: April 22, 2026

     BGPT Author Review



    Scientific Quality

    20%

    The provided Xueying Yuan publications appear to be in finance/ESG/greenwashing rather than biology, so bio-scientific rigor/novelty cannot be evaluated from biological evidence. Citation metrics provided (35 citations, h-index 3 across 4 papers) suggest limited impact, but domain mismatch and missing methods prevent an informed biological assessment.



    Communication Quality

    40%

    No writing samples, abstracts, figures, or argumentative structure were provided, so communication quality can’t be assessed directly; scoring is low due to missing evidence rather than confirmed poor communication.



    Author Novelty

    30%

    Without content-level detail (methods/assays/results), novelty can’t be judged; title-level cues suggest applied modeling/empirical ESG work, which is often incremental unless distinct methodological breakthroughs are shown.



    Scientific Rigor

    20%

    No experimental or methodological details were provided, and the work appears non-biological; therefore scientific rigor cannot be verified. Name-disambiguation risk further reduces trust in any metric attribution.

     Hypothesis Graveyard



    That the provided list demonstrates biological/mechanistic cancer immunology rigor—this is unlikely because the listed titles don’t match biological experimental topics.


    That citation metrics alone establish scientific merit in biology—this is not warranted because impact measures are domain- and field-dependent and can be confounded by indexing and community size.

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT